Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Non-nucleoside reverse transcriptase inhibitors Stories

2014-02-19 11:04:05

Pittsburgh researchers show how therapy-induced resistance to 'NNRTI' drugs works at 58th Annual Biophysical Society Meeting in San Francisco For the more than one million people with HIV/AIDS in the United States (and the over 34 million people living with HIV/AIDS around the world), antiretroviral drugs such as efavirenz and other so-called non-nucleoside reverse transcriptase inhibitors (NNRTIs) in combination with other antiretrovirals can be a lifeline, because they slow the progress...

2013-05-01 14:56:37

Researchers from CHOP, Penn find better outcomes for efavirenz over nevirapine in children over age 3 in low-resource settings Researchers from The Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more...

HIV Antiretroviral Drug Has Psychoactive Effects
2013-04-22 05:22:19

redOrbit Staff & Wire Reports - Your Universe Online The psychoactivity of an antiretroviral (ARV) drug commonly used to treat HIV has been linked to its recreational use, according to research presented during the Experimental Biology 2013 conference in Boston, Massachusetts on Sunday. The medication efavirenz (which is also known under the brand names Sustiva and Stocrin) has become popular as a treatment for the virus that causes AIDS due to its ability to suppress replication of...

2013-03-04 12:28:21

Interim Phase 3 STARTVerso(TM) 4 analysis in co-infected patients showed 80% protocol-defined early treatment success* RIDGEFIELD, Conn., March 4, 2013 /PRNewswire/ -- Today Boehringer Ingelheim Pharmaceuticals, Inc. announced the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso(TM). These results, from the Phase 3 trial STARTVerso(TM) 4, were presented today at the 20(th) annual Conference on...

2012-12-10 16:24:00

TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT(®) for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults....

2012-11-29 14:36:09

A combination of anti-HIV drugs has been found to also reduce the risk of recurrent malaria by nearly half among HIV-positive children, according to researchers supported by the National Institutes of Health. The combination of protease inhibitors lopinavir and ritonavir contributed to an overall reduction of 40 percent in the rate of malaria among a group of HIV-positive infants and children up to 6 years old in Uganda who were also being treated with anti-malarial drugs. This...

2012-07-24 10:10:48

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30...

2012-07-23 20:35:11

Included in the 2012 International Antiviral Society-USA panel recommendations for human immunodeficiency virus (HIV) patient care is that all adult patients, regardless of CD4 cell count, should be offered antiretroviral therapy (ART), according to an article in the July 25 issue of JAMA, a theme issue on HIV/AIDS. Other new recommendations include changes in therapeutic options and modifications in the timing and choice of ART for patients with an opportunistic illness such as tuberculosis....

2012-06-22 06:15:16

(Ivanhoe Newswire) -- About 0.2% of pregnant women are HIV positive and 1/3 will pass the virus to their baby before it is born if no treatment is given. A new study breaches the safety and efficacy of adding antiretroviral drugs (HIV treatment drugs) to standard zidovudine prophylaxis (standard HIV prevention drugs) in infants of mothers with HIV who did not receive antenatal antiretroviral therapy because of late identification. Within 48 hours after their birth, researchers randomly...

2012-06-21 17:29:44

Non-breastfed babies born to HIV-positive mothers who didn't receive antiretroviral therapy during pregnancy are routinely given zidovudine, commonly known as AZT, shortly after birth to prevent mother-to-child transmission of the virus that causes AIDS. While effective, this strategy doesn't always protect the infant from acquiring the virus during the mother's labor and delivery. But a new UCLA-led study published June 21 in the New England Journal of Medicine finds that a two- or...